tropical diseases

bug malaria mosquito

Biotech

Merck admits defeat in chikungunya vaccine race with Valneva

Once competing with Valneva to get a chikungunya shot to market, it looks like Merck & Co. has admitted defeat as its rival reaches the finish line.

James Waldron Feb 2, 2023 11:07am

Novartis building

Racing resistance, Novartis plans pivotal malaria drug trial

Nov 23, 2022 7:20am

Novartis, GSK commit $1.25B to tropical disease R&D

Jun 23, 2022 5:52am

valneva

Valneva exceeds protection goal in chikungunya vaccine trial

Aug 5, 2021 7:40am

mosquito close up on skin against a green background

Takeda’s dengue shot keeps 84% of kids out of hospital

May 23, 2021 11:49pm

mosquito-malaria

Gates, Merck and Novartis-backed Adjuvant Capital raises $300M

Feb 18, 2021 7:45am